Biocracked
**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
Research

Kepiye Cara Kerja CBL-514? Iki Ilmu Penjenengané

Dr. Synapse · · 4 min read

Kepiye Cara Kerja CBL-514? Iki Ilmu Penjenengané

Klaim sing menarik bab CBL-514 dudu yen iku "nglumer" lemak. Klaimé yaiku nyurung sel lemak supaya mlebu proses mateni sel sing diarani apoptosis, ing wilayah sing disuntik. Bédané iki nentokake kabeh bab senyawa iki: apa sing dikira‑kira kudu dilakokaké, apa sing diteliti, lan apa sing bukti ne bisa lan ora bisa nuduhaké.

Cathetan bab jeneng: senyawa iki CBL‑514, dudu "CL‑514". Iki molekul cilik sing disuntikaké lan diteliti dening Caliway Biopharmaceuticals (New Taipei City, Taiwan). Dudu suplemen, dudu tablet oral, lan dudu produk konsumen sing wis disetujoni. Ing riset sing dibahas kéné, para peneliti ing uji klinis maringi suntikan subkutan ing lemak perut.

Klaim Molekuler: DYRK1b, caspase‑3, lan Bax/Bcl‑2

Tulisan fase 2 taun 2025 nerangaké CBL‑514 minangka "agen injeksi molekul cilik kanggo lipolisis sing ndorong apoptosis adiposit lan pangurangan lemak subkutan sing tertarget ing studi nonklinis." Mekanisme sing luwih spesifik asalé saka tulisan fase 2a sadurungé (Goodman et al., 2022). Tulisan iku nyatakake yen studi nonklinis nuduhaké CBL‑514:

  • ngendhegake DYRK1b, kinase sing njaga uripe sel;
  • nggedhekake mediator apoptosis caspase‑3 lan Bax/Bcl‑2;
  • ngasilake apoptosis adiposit sing gumantung dosis ing in‑vitro lan in‑vivo.

Tulisan fase 2a uga nglaporake lipolisis ing in‑vitro lan pangurangan adipositas subkutan ing wilayah sing ditarget ing studi kewan.

Ing tembung sederhana, usulané yaiku obat iki ngganggu sinyal urip ing sel lemak lan nggeser keseimbangan marang mesin mateni sel dhewe. Caspase‑3 iku enzim eksekutor utama ing apoptosis. Rasio Bax/Bcl‑2 dadi cara standar kanggo mriksa apa sel lagi condong marang pati utawa urip.

Apa sing Durung Diketahui

Ana cathetan penting. Temuan nonklinis iki diparingi laporan rahasia Caliway sing ora dipublikasikaké, saéngga sing dilaporake mung saka pihak perusahaan lan ora dijlentrehaké kanthi mandiri ing metodhe tulisan fase 2. Tulisan sing dipublikasikaké uga ora nerangake struktur kimia CBL‑514. Tanpa struktur iki, sapa wae njaba perusahaan ora bisa mangertèni apa molekulé, carane ngiket DYRK1b, utawa apa inhibisi DYRK1b kuwi pancen inti saka mekanisme.

Mati Sel Lemak Lokal, Dudu Peningkatan Metabolik

Mekanisme sing diusulaké ora ngenani nambah tingkat metabolisme utawa panggunaan energi awak sakabèhé. Strateginé lokal: suntikaké ing lemak subkutan perut, mateni sel lemak ing kana, lan delengen apa ana penurunan ketebalan lan volume lemak sing bisa diukur nganggo ultrasonik.

Data bobot ing fase 2 cocok karo kerangka iki. Rata‑rata perubahan bobot badan mung sithik: +0,45 kg ing minggu kaping 4 lan +0,02 kg ing minggu kaping 8 ing kelompok CBL‑514, dibandhingake karo -0,76 kg lan -0,26 kg ing placebo. Penulis nglaporaké ora ana perubahan signifikan ing rata‑rata bobot utawa BMI, lan nyebutaké yèn penurunan lemak lokal kedadeyan sanajan ana peserta sing nambah bobot luwih saka 1 kg (data ora ditampilaké). Iki crita volume lemak lokal, dudu crita ngurangi bobot.

Apa sing Diukur Ing Uji Manungsa

Studi fase 2 (Gold et al., Aesthetic Surgery Journal, 2025) randomisasi, single‑blind, lan kontrol placebo, dilakokaké ing limang pusat ing Amerika Serikat lan Australia. Peserta nampa nganti patang perlakuan kanthi interval 4 minggu. Saben suntikan nyedhiyakake 2,4 mL CBL‑514 kanthi konsentrasi 2 mg/cm², maksimal 600 mg per perlakuan, utawa saline placebo. Volume lemak diitung saka ketebalan ultrasonik ing papat titik pindai sing dikalikan wilayah perlakuan sing didefinisike 300 cm².

Penulis nyatakake yèn uji iki nggayuh end‑point utama. Ing analisis intention‑to‑treat, 63,9 % peserta CBL‑514 (23/36) nduwèni paling ora 150 mL penurunan volume lemak ing minggu kaping 4, dibandhingake karo 17,4 % (4/23) ing placebo. Ing minggu kaping 8 perséntase iku dadi 69,6 % (16/23) versus 0,0 % (0/16). Perubahan rata‑rata kuadrat paling cilik saka baseline ing kelompok CBL‑514 yaiku -199,80 mL ing minggu kaping 4 lan -209,46 mL ing minggu kaping 8.

Iki asil‑e. Iku ora bukti mekanisme. Uji iki mung ngukur volume, ketebalan, foto, lan keamanan. Ora ana data biopsi utawa caspase saka manungsa, dadi ora ana sing nuduhaké yèn inhibisi DYRK1b utawa apoptosis adiposit bener‑bener kedadeyan ing peserta. Data manungsa mung nuduhaké yèn ketebalan lemak ing ultrasonik mudhun. Penjelasan apoptosis tetep dadi hipotesis sing dijupuk saka karya nonklinis.

Maca Hasil Kanthi Ati‑ati

Sawetara watesan penting kanggo sapa wae sing nggatekake crita mekanisme iki:

  • Mung single‑blind. Peserta diwenehi buta, nanging peneliti, staf situs, lan sponsor ora.
  • Dropout dhuwur. Saka 75 peserta sing dirawat, 37 (49,3 %) ora ngrampungaké studi. Jumlah denominator nyusut ing saben tindak lanjut, lan populasi per‑protokol mung 30 wong.
  • Keterlibatan sponsor. Caliway melu ing desain studi, pangumpulan lan analisis data, interpretasi, penulisan, lan keputusan kanggo ngirim artikel.
  • Ukuran sampel eksploratori lan ora ana penyesuaian kanggo tes ganda.
  • Mayoritas peserta wanita (94,0 % ing kelompok CBL‑514).

Para penulis ngandharaké yèn hasilé "padha karo sing dipikolehi saka liposuction" lan yèn tren "katingal luwih gedhé" tinimbang sawetara studi kriolipolisis. Iki interpretasi saka penulis. Cara pangukuran béda, lan ora ana perbandingan langsung.

Bedane karo ATX‑101

Siji-sijine injeksi sing wis disetujoni FDA kanggo pengurangan lemak sing disebut ing artikel yaiku ATX‑101 (asam deoksikolik, Kybella), sing disetujoni mung kanggo lemak submental (ngisor dagu). Obat iki kerja liwat adipositolisis, sing beda karo cara apoptosis sing diusulaké CBL‑514, lan artikel kasebut ngetokaké kekhawatiran babagan selektivitas jaringané. CBL‑514 digambaraké minangka nyurung pangurangan lemak tertarget tanpa nekrosis kulit, ulserasi, utawa cedera saraf ing karya nonklinis. Penulis fase 2 ora nyatakake kedadeyan iki ing trialé.

Iku sawijining pengamatan saka siji studi menengah, ora bukti keunggulan keamanan jangka panjang. Uji iki cilik, nduwèni attrisi signifikan, lan ora dirancang kanggo njawab pitakon keamanan perbandingan.

Simpulan

Mekanisme sing diusulaké CBL‑514 cetha: ngendhegake DYRK1b, nambah caspase 3 lan Bax/Bcl‑2, lan ndorong apoptosis adiposit sing gumantung dosis ing wilayah sing disuntik. Data manungsa nuduhaké pangurangan lemak sing diukur ultrasonik lokal dibandhingake karo placebo. Hubungan antarane loro mau durung dibuktekaké ing wong, lan bukti molekuler asalé saka laporan perusahaan sing ora dipublikasikaké. CBL‑514 tetep eksperimental, lan artikel iki dudu pandhuan panggunaan.

Sumber

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

Injeksi Lipolisis CBL-514: Peta Bukti Fase II

BY DR. SYNAPSE ·

CBL-514 yaiku suntikan molekul cilik sing lagi diteliti supaya sel lemak (adiposit) ngalami apoptosis lan njalari pangurangan kantong lemak ing weteng. Ing uji fase II sing dilakokaké ing taun 2025 kanthi 76 peserta acak, volume lemak sing diukur nganggo ultrasound nyusut drastis dibandhingake karo saline, nanging bobot awak ora owah. Tulisan iki nerangake desain, dosis 2 mg/cm², data efektifitas lengkap karo denominator sing saya cilik, lan mekanisme DYRK1b‑caspase sing dilaporaké perusahaan. Nanging uga disorot watesan penting: desain siji‑blind, peran sponsor, attrisi 49 %, follow‑up sing cekak, lan mayoritas partisipan wanita.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Dosis CBL‑514 – Apa sing Dikatakan Ilmu?

BY DR. SYNAPSE ·

Trial CBL‑514 iku protokol injeksi investigasional, lan angka “600 mg” iku wates maksimum saben perawatan, dudu dosis suplemen. Artikel iki nerangaké studi fase 2a sing nggolèki dosis (1,2, 1,6, lan 2,0 mg/cm² ing area 150 cm², n=43, open‑label) lan nerangaké asal‑usul angka 24,96 % sing asring disebut. Banjur dibahas fase 2 kanthi kontrol plasebo, sing tetep nganggo 2,0 mg/cm² nanging nambah area dadi 300 cm² lan wates dadi 600 mg. Sampeyan bakal ngerti kenapa total mg ora bisa dibandhingaké antarane studi, apa sing dilaporaké babagan keamanan, lan kenapa iki isih ora disetujui utawa dadi saran.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Apa CBL‑514 Tenan Ngobong Lemak? Kabeh Sing Kita Ngerti

BY HELIX WARD ·

Uji coba fase 2 CBL‑514 ing taun 2025 ora ngukur penurunan bobot awak, nanging nyoba apa suntikan langsung menyang jaringan lemak ing weteng bisa ngurangi paling ora 150 mL volume lemak subkutan sing diukur nganggo ultrasonik. Sawisé wolung minggu, 69,6 % (16 saka 23) partisipan sing nampa CBL‑514 nganti target iki, dene kelompok plasebo ora ana sing nggayuh. Nanging rata‑rata bobot awak malah ora mudhun (+0,02 kg), separo partisipan ora ngrampungake studi, lan jumlah partisipan sing netepi protokol mung 30 wong. Reaksi situs suntikan umum, kaya owah‑warna (71,4 %) lan rasa lara sing serius (18,4 %).

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Injeksi Penghilangan Lemak CBL-514: Apa Kata Ilmu?

BY DR. SYNAPSE ·

CBL-514 saiki wis liwat uji coba acak fase 2 sing dikontrol plasebo lan diterbitaké ing *Aesthetic Surgery Journal*. Penulis nglaporaké yèn uji iki nyukupi titik akhir utama lan sekunder, nanging desainé duwé akèh kekurangan: mung siji‑blind, sponsor melu ngrancang, nganalisa, lan nulis studi, lan tingkat drop‑out meh separo. Saka 75 peserta sing mlebu, mung 38 sing rampung, lan populasi sing diteliti mayoritas wanita lan kulit putih. Ing ngisor iki apa sing bisa didhukung uji iki, apa sing ora, lan kenapa iki dudu saran medis utawa bukti perawatan sing wis disetujui.

This page is available in